Patient Preferences For Chemotherapy In The Treatment Of Non-Small Cell Lung Cancer: A Multicenter Discrete Choice Experiment (DCE) Study In China

References

• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108. doi:10.3322/caac.2126225651787
   PubMed Web of Science ®Google Scholar
• Chen WQ, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–132. doi:10.3322/caac.2133826808342
   PubMed Web of Science ®Google Scholar
• Chen WQ, Sun KX, Zheng RS, et al. Report of cancer incidence and mortality in different areas of China, 2014. China Cancer. 2018;27:1-14.
   Google Scholar
• Cai Y, Yan BH, Zhou GW. Analysis of direct economic burden and average hospitalization cost of lung cancer in China in 2011–2015. Chin J Health Stat. 2018;35:334-337.
   Google Scholar
• Ettinger DS, Wood DE, Akerley W, et al. NCCN guidelines insights: non-small cell lung cancer, version 4.2016. J Natl Compr Canc Netw. 2016;14:255–264. doi:10.6004/jnccn.2016.003126957612
   PubMed Web of Science ®Google Scholar
• Reck M, Popat S, Reinmuth N, et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl 3):i27–i39. doi:10.1093/annonc/mdu199
   Web of Science ®Google Scholar
• Postmus PE, Kerr KM, Oudkerk M, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:v1–v21. doi:10.1093/annonc/mdx222
   Web of Science ®Google Scholar
• Ramalingam S, Belani C. Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. ONCOLOGIST. 2008;13(Suppl 1):5–13. doi:10.1634/theoncologist.13-S1-518263769
   PubMed Web of Science ®Google Scholar
• Hack TF, Degner LF, Watson P, Sinha L. Do patients benefit from participating in medical decision making? Longitudinal follow-up of women with breast cancer. Psychooncology. 2006;15:9–19. doi:10.1002/pon.90715669023
   PubMed Web of Science ®Google Scholar
• Hopmans W, Damman OC, Senan S, et al. A patient perspective on shared decision making in stage I non-small cell lung cancer: a mixed methods study. BMC Cancer. 2015;15:959. doi:10.1186/s12885-015-1584-326673216
   PubMed Web of Science ®Google Scholar
• Kehl KL, Landrum MB, Arora NK, et al. Association of actual and preferred decision roles with patient-reported quality of care: shared decision making in cancer care. Jama Oncol. 2015;1:50–58. doi:10.1001/jamaoncol.2014.11226182303
   PubMed Web of Science ®Google Scholar
• Mokhles S, Nuyttens J, de Mol M, et al. Treatment selection of early stage non-small cell lung cancer: the role of the patient in clinical decision making. BMC Cancer. 2018;18:79. doi:10.1186/s12885-018-4242-829334910
   PubMed Web of Science ®Google Scholar
• Arora NK, McHorney CA. Patient preferences for medical decision making: who really wants to participate? Med Care. 2000;38:335–341. doi:10.1097/00005650-200003000-0001010718358
   PubMed Web of Science ®Google Scholar
• Spatz ES, Spertus JA. Shared decision making: a path toward improved patient-centered outcomes. Circ Cardiovasc Qual Outcomes. 2012;5:e75–e77. doi:10.1161/CIRCOUTCOMES.112.96971723170005
   PubMed Web of Science ®Google Scholar
• Sekimoto M, Asai A, Ohnishi M, et al. Patients’ preferences for involvement in treatment decision making in Japan. BMC Fam Pract. 2004;5:1. doi:10.1186/1471-2296-5-115053839
   PubMedGoogle Scholar
• Li Z, Jiang S, He R, et al. Trajectories of hospitalization cost among patients of end-stage lung cancer: a retrospective study in China. Int J Environ Res Public Health. 2018;15(12):2877. doi:10.3390/ijerph15061188
   Web of Science ®Google Scholar
• Shi YK, Wang L, Han BH, et al. First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study. Ann Oncol. 2017;28:2443–2450. doi:10.1093/annonc/mdx35928945850
   PubMed Web of Science ®Google Scholar
• Shi Y, Zhang L, Liu X, et al. Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. Lancet Oncol. 2013;14:953–961. doi:10.1016/S1470-2045(13)70355-323948351
   PubMed Web of Science ®Google Scholar
• Marshall D, Bridges JF, Hauber B, et al. Conjoint analysis applications in health – how are studies being designed and reported: an update on current practice in the published literature between 2005 and 2008. PATIENT. 2010;3:249–256. doi:10.2165/11539650-000000000-0000022273432
   PubMedGoogle Scholar
• Orme B. Getting Started with Conjoint Analysis: Strategies for Product Design and Pricing Research. Madison, WI: Research Publishers LLC; 2006.
   Google Scholar
• Ryan M, Gerard K. Using discrete choice experiments to value health care programmes: current practice and future research reflections. Appl Health Econ Health Policy. 2003;2:55–64.14619274
   PubMedGoogle Scholar
• de Bekker-Grob EW, Ryan M, Gerard K. Discrete choice experiments in health economics: a review of the literature. Health Econ. 2012;21:145–172. doi:10.1002/hec.169722223558
   PubMed Web of Science ®Google Scholar
• Hauber AB, Gonzalez JM, Groothuis-Oudshoorn CG, et al. Statistical methods for the analysis of discrete choice experiments: a report of the ISPOR conjoint analysis good research practices task force. Value Health. 2016;19:300–315. doi:10.1016/j.jval.2016.04.00427325321
   PubMed Web of Science ®Google Scholar
• Ryan MGKAM. Using Discrete Choice Experiments to Value Health and Health Care. Dordrecht, The Netherlands: Springer; 2008.
   Google Scholar
• Lancsar E, Louviere J. Conducting discrete choice experiments to inform healthcare decision making: a user’s guide. Pharmacoeconomics. 2008;26:661–677. doi:10.2165/00019053-200826080-0000418620460
   PubMed Web of Science ®Google Scholar
• Lancsar E, Fiebig DG, Hole AR. Discrete choice experiments: a guide to model specification, estimation and software. Pharmacoeconomics. 2017;35:697–716. doi:10.1007/s40273-017-0506-428374325
   PubMed Web of Science ®Google Scholar
• Bridges JF, Hauber AB, Marshall D, et al. Conjoint analysis applications in health – a checklist: a report of the ISPOR good research practices for conjoint analysis task force. Value Health. 2011;14:403–413. doi:10.1016/j.jval.2010.11.01321669364
   PubMed Web of Science ®Google Scholar
• Hensher DARJGW. Applied Choice Analysis: A Primer. Cambridge: Cambridge University Press; 2005.
   Google Scholar
• Hirose T, Horichi N, Ohmori T, et al. Patients preferences in chemotherapy for advanced non-small-cell lung cancer. Intern Med. 2005;44:107–113. doi:10.2169/internalmedicine.44.10715750269
   PubMed Web of Science ®Google Scholar
• Silvestri G, Pritchard R, Welch HG. Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews. BMJ. 1998;317:771–775. doi:10.1136/bmj.317.7161.7719740561
   PubMed Web of Science ®Google Scholar
• Bridges JF, Mohamed AF, Finnern HW, et al. Patients’ preferences for treatment outcomes for advanced non-small cell lung cancer: a conjoint analysis. Lung Cancer. 2012;77:224–231. doi:10.1016/j.lungcan.2012.01.01622369719
   PubMed Web of Science ®Google Scholar
• Muhlbacher AC, Bethge S. Patients’ preferences: a discrete-choice experiment for treatment of non-small-cell lung cancer. Eur J Health Econ. 2015;16:657–670. doi:10.1007/s10198-014-0622-425135768
   PubMed Web of Science ®Google Scholar
• Bridges JF, Jones C. Patient-based health technology assessment: a vision of the future. Int J Technol Assess Health Care. 2007;23:30–35. doi:10.1017/S026646230705154917234014
   PubMed Web of Science ®Google Scholar
• Blinman P, Alam M, Duric V, et al. Patients’ preferences for chemotherapy in non-small-cell lung cancer: a systematic review. Lung Cancer. 2010;69:141–147. doi:10.1016/j.lungcan.2010.05.00120570009
   PubMed Web of Science ®Google Scholar
• Li B, Ren S, Wang Y, et al. Efficacy of third-generation chemotherapeutic agents combined with cisplatin or carboplatin in 3100 Chinese patients with advanced non-small-cell lung cancer. Thorac Cancer. 2013;4:117–122. doi:10.1111/j.1759-7714.2012.00173.x28920197
   PubMed Web of Science ®Google Scholar
• Luo L, Hu Q, Jiang JX, et al. Comparing single-agent with doublet chemotherapy in first-line treatment of advanced non-small cell lung cancer with performance status 2: a meta-analysis. Asia Pac J Clin Oncol. 2015;11:253–261. doi:10.1111/ajco.1235925866140
   PubMed Web of Science ®Google Scholar
• de Castria TB, Da SE, Gois AF, et al. Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer. Cochrane Database Syst Rev. 2013;8:CD009256.
   Web of Science ®Google Scholar
• Schuette WH, Groschel A, Sebastian M, et al. A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer. Clin Lung Cancer. 2013;14:215–223. doi:10.1016/j.cllc.2012.10.00123332288
   PubMed Web of Science ®Google Scholar
• Kim ES, Moon J, Herbst RS, et al. Phase II trial of carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab in advanced nonsquamous non-small-cell lung cancer: SWOG S0536. J Thorac Oncol. 2013;8:1519–1528. doi:10.1097/JTO.000000000000000924189513
   PubMed Web of Science ®Google Scholar
• Hattori Y, Satouchi M, Katakami N, et al. A phase II study of pemetrexed in patients with previously heavily treated non-squamous non-small cell lung cancer (HANSHIN Oncology Group 001). Cancer Chemother Pharmacol. 2014;73:17–23. doi:10.1007/s00280-013-2290-y24141372
   PubMed Web of Science ®Google Scholar
• Zhou C, Wu YL, Chen G, et al. BEYOND: a randomized, double-blind, placebo-controlled, multicenter, phase III study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in Chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer. J Clin Oncol. 2015;33:2197–2204. doi:10.1200/JCO.2014.59.442426014294
   PubMed Web of Science ®Google Scholar
• Yang CC, Hu Q, Liu YJ. Progress in research on disease burden of non-small cell lung cancer. China Licensed Pharmacist. 2016;13:40–45.
   Google Scholar
• XL W. Clinical effect and pharmacoeconomics of gefitinib and erlotinib in advanced non-small-cell lung cancer. China Medicine and Pharmacy. 2015;05:100–102.
   Google Scholar
• Zhang MM, Pang TY, Gao WH. Pharmacoeconomics evaluations of four different chemotherapy regimens against advanced non-small cell lung cancer. Chin Hosp Pharm J. 2016;36:2001–2004.
   Google Scholar
• Reed JF, Lancsar E, Marshall D, et al. Constructing experimental designs for discrete-choice experiments: report of the ISPOR conjoint analysis experimental design good research practices task force. Value Health. 2013;16:3–13. doi:10.1016/j.jval.2012.08.222323337210
   PubMed Web of Science ®Google Scholar
• Burgess L, Street DJ. Optimal designs for choice experiments with asymmetric attributes. J Stat Plan Infer. 2005;134:288–301. doi:10.1016/j.jspi.2004.03.021
   Web of Science ®Google Scholar
• Kuhfeld’s WF. Marketing Research Methods in SAS: Experimental Design, Choice, Conjoint and Graphical Techniques. Cary, NC: SAS Institute Inc; 2010.
   Google Scholar
• Train KE. Discrete Choice Methods with Simulation. Cambridge: Cambridge University Press; 2003.
   Google Scholar
• Bech M, Gyrd-Hansen D. Effects coding in discrete choice experiments. Health Econ. 2005;14:1079–1083. doi:10.1002/hec.98415852455
   PubMed Web of Science ®Google Scholar
• Brundage MD, Davidson JR, Mackillop WJ. Trading treatment toxicity for survival in locally advanced non-small cell lung cancer. J Clin Oncol. 1997;15:330–340. doi:10.1200/JCO.1997.15.1.3308996160
   PubMed Web of Science ®Google Scholar
• Brundage MD, Feldman-Stewart D, Cosby R, et al. Cancer patients’ attitudes toward treatment options for advanced non-small cell lung cancer: implications for patient education and decision support. Patient Educ Couns. 2001;45:149–157. doi:10.1016/s0738-3991(01)00155-011687329
   PubMed Web of Science ®Google Scholar
• Hirose T, Yamaoka T, Ohnishi T, et al. Patient willingness to undergo chemotherapy and thoracic radiotherapy for locally advanced non-small cell lung cancer. Psychooncology. 2009;18:483–489. doi:10.1002/pon.145018942662
   PubMed Web of Science ®Google Scholar